On Wednesday, October 22nd, Mount Sinai Hospital (Toronto, Ontario) and Hospital Universitario Austral (Buenos Aires, Argentina) enrolled the 59th and 60th patients in the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial, respectively, thereby completing enrolment for the pilot phase of the study. The PARITY pilot has proven feasibility of a Canadian multi-centre randomized controlled trial in orthopaedic oncology. Indeed, the pilot phase exceeded expectations by successfully expanding internationally to sites in the United States, Australia and Argentina. As a result of this early success, these pilot phase patients will be rolled into the definitive phase sample size of 600 patients.
The PARITY trial is investigating whether long duration post-operative prophylactic antibiotics decreases the rate of surgical site infections compared to standard shorter duration among patients undergoing surgical excision and endoprosthetic reconstruction of lower extremity bone tumors. Led by Dr. Michelle Ghert, PARITY is the first rigorously designed trial in the field of orthopaedic oncology and has the potential to significantly impact clinical practice and establish a collaborative network worldwide for future research in the field. Prior to PARITY, orthopaedic oncologists doubted that prospective multi-centre randomized trials were possible in their specialty. The success of the PARITY pilot has demonstrated that these types of study are, in fact, possible.